Emily Bader on Muck Rack

Emily Bader

(She/Her)
New Jersey
As seen in: Oncology News Central, MSN, Yahoo News, Associated Press, Rotten Tomatoes, Yahoo Sports, Yahoo, moviefone, JustWatch, NewsBreak, Insurance Journal and
Covers:  New Jersey business news, healthcare, policy, pharma
Editor covering business, policy & health @OncNewsCentral📰 NJ news reporter roots Shore girl with strong opinions but an even stronger coffee

Get in touch with Emily

Contact Emily, search articles and posts on X, monitor coverage, and track replies from one place.

Learn more about Muck Rack

Actions

Share this page

Emily Bader’s Journalist Portfolio

View article →
Vanguard launches online health service for better patient access to care

Vanguard launches online health service for better patient access to care

Fairfield-based Vanguard Medical Group recently announced the launch of Vanguard eCare, an online diagnosis a…

View article →

Articles

Oncology Drugs Fast-Tracked by the FDA in April 2026

|
By Emily Bader
| Oncology News Central
In April, the U.S. Food and Drug Administration (FDA) granted fast track designation to drugs used for ovarian, bladder, pancreatic, and other cancers. Here are some key highlights.
Open in Who Shared Issue with article?

Phase 3 Breast Cancer Data Signal Big Shifts in Care Ahead

|
By Emily Bader
| Oncology News Central
Recent phase 3 data presented at the 2025 San Antonio Brest Cancer Symposium (SABCS) point to evolving standards of care in breast cancer. Here are some of the highlights. Phase 3 data from the IidERA trial presented at SABCS 2025 suggest the investigational oral selective estrogen receptor degrader giredestrant may represent the first major advance in adjuvant endocrine therapy for early-stage ER-positive, HER2-negative breast cancer in more than two decades.
Open in Who Shared Issue with article?

Phase 3 Trials Change Practice in Colorectal Cancer

|
By Emily Bader
| Oncology News Central
Phase 3 data presented at the 2026 American Society of Clinical Oncology Gastrointestinal Cancers Symposium (ASCO GI 2026) and results from other key trials may change standards of care in colorectal cancer (CRC). Here is a roundup of some recent highlights. In January, two phase 3 studies presented at ASCO GI 2026 highlighted distinct first-line advances for molecularly defined subsets of patients with metastatic CRC.
Open in Who Shared Issue with article?
See all 5,479 licensed articles (5,481 Total)

Actions

Share this page

Is this you?

As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work.
Claim your profile

Get in touch with Emily

Contact Emily, search articles and posts on X, monitor coverage, and track replies from one place.

Learn more about Muck Rack
 •  Privacy  •  Terms  •  Security and Legal  •   •   •   • 

© 2026 Muck Rack

SOC 2® Certified